News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PAION Completes First Part of Phase Ib Study of the Anesthetic/Sedative CNS 7056



5/11/2009 10:39:54 AM

AACHEN, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the positive results of the first part of the Phase Ib study with the new short-acting intravenous anesthetic/sedative CNS 7056, which further strengthen the safety profile of the compound.

Read at BioSpace.com


comments powered by Disqus
PAION AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES